Home > Insider Trading > Filing (0001209191-21-038786)

Filing Details

Accession Number:: 0001209191-21-038786
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-07 21:21:44
Reporting Period:: 2021-06-03

Accepted Time:: 2021-06-07 21:21:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1697532	Applied Therapeutics Inc.	APLT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1775410	Riccardo Perfetti	C/O Applied Therapeutics, Inc. 545 5Th Avenue, Suite 1400 New York NY 10017	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-06-03	460	$1.44	460	No	4	M	Direct
Common Stock	Disposition	2021-06-03	460	$19.66	0	No	4	S	Direct
Common Stock	Acquisiton	2021-06-04	460	$1.44	460	No	4	M	Direct
Common Stock	Disposition	2021-06-04	460	$19.65	0	No	4	S	Direct
Common Stock	Acquisiton	2021-06-07	460	$1.44	460	No	4	M	Direct
Common Stock	Disposition	2021-06-07	200	$20.43	260	No	4	S	Direct
Common Stock	Disposition	2021-06-07	260	$21.38	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-06-03	460	$0.00	460	$1.44
Common Stock	Stock Option (Right to Buy)	Disposition	2021-06-04	460	$0.00	460	$1.44
Common Stock	Stock Option (Right to Buy)	Disposition	2012-06-07	460	$0.00	460	$1.44

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
170,514	2028-12-16	No	4	M	Direct
170,054	2028-12-16	No	4	M	Direct
169,594	2028-12-16	No	4	M	Direct

Footnotes

Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.4900 to $19.7900 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.5400 to $19.9000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.9700 to $20.8300 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.2900 to $21.4500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.